Prognostic significance of pretreatment serum β2-microglobulin levels in multiple myeloma
- 1 October 1983
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 19 (10), 1361-1364
- https://doi.org/10.1016/0277-5379(93)90004-o
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Serum β 2-microglobulin in myelomatosis: potential value in stratification and monitoringBritish Journal of Cancer, 1980
- β2-MICROGLOBULIN, A TUMOUR MARKER OF LYMPHOPROLIFERATIVE DISORDERSThe Lancet, 1978
- Serum β2-microglobulin in controls and cancer patientsClinica Chimica Acta; International Journal of Clinical Chemistry, 1977
- β2-Microglobulin levels in cancerous and other disease statesClinica Chimica Acta; International Journal of Clinical Chemistry, 1976
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975
- β2-Microglobulin: occurrence in fetal life and malignancyClinica Chimica Acta; International Journal of Clinical Chemistry, 1974
- Serum β2-microglobulin in various disordersClinica Chimica Acta; International Journal of Clinical Chemistry, 1973
- The Serum Levels and Urinary Excretion of β2-Microglobulin in Apparently Healthy SubjectsScandinavian Journal of Clinical and Laboratory Investigation, 1972
- Isolation and Properties of a Low Molecular Weight β2-Globulin Occurring in Human Biological FluidsPublished by Elsevier ,1968
- Microglobulinaemia in Renal FailureNature, 1968